Published in Qual Life Res on April 01, 2010
Cost-effectiveness of adjuvant FOLFOX and 5FU/LV chemotherapy for patients with stage II colon cancer. Med Decis Making (2013) 0.84
"Married with children" the influence of significant others in TTO exercises. Health Qual Life Outcomes (2015) 0.84
Assessing health-state utility values in patients with metastatic colorectal cancer: a utility study in the United Kingdom and the Netherlands. Int J Colorectal Dis (2014) 0.79
Cost-effectiveness of pazopanib compared with sunitinib in metastatic renal cell carcinoma in Canada. Curr Oncol (2016) 0.77
Systematic review of health state utility values for economic evaluation of colorectal cancer. Health Econ Rev (2016) 0.77
Comparative economics of a 12-gene assay for predicting risk of recurrence in stage II colon cancer. Pharmacoeconomics (2014) 0.76
"Back to the future": Influence of beliefs regarding the future on TTO answers. Health Qual Life Outcomes (2016) 0.75
Estimating utility weights and quality-adjusted life year loss for colorectal cancer-related health states in Korea. Sci Rep (2017) 0.75
Revised Bethesda Guidelines for hereditary nonpolyposis colorectal cancer (Lynch syndrome) and microsatellite instability. J Natl Cancer Inst (2004) 14.97
A randomized trial of vertebroplasty for osteoporotic spinal fractures. N Engl J Med (2009) 10.06
Effect of VKORC1 haplotypes on transcriptional regulation and warfarin dose. N Engl J Med (2005) 8.77
Expenditures and health status among adults with back and neck problems. JAMA (2008) 6.11
Association between CYP2C9 genetic variants and anticoagulation-related outcomes during warfarin therapy. JAMA (2002) 5.26
Rapid magnetic resonance imaging vs radiographs for patients with low back pain: a randomized controlled trial. JAMA (2003) 4.52
Global epidemiology of hepatitis B virus. J Clin Gastroenterol (2004) 4.48
Surgery versus non-surgical therapy for carpal tunnel syndrome: a randomised parallel-group trial. Lancet (2009) 4.05
A national cancer clinical trials system for the 21st century: reinvigorating the NCI Cooperative Group Program. J Natl Cancer Inst (2010) 4.04
A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose. Blood (2008) 4.02
Washington State cancer patients found to be at greater risk for bankruptcy than people without a cancer diagnosis. Health Aff (Millwood) (2013) 3.69
Expanding the evidence base in transplantation: the complementary roles of randomized controlled trials and outcomes research. Transplantation (2008) 3.43
Spinal cord stimulation for failed back surgery syndrome: outcomes in a workers' compensation setting. Pain (2009) 3.19
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force--7. Value Health (2012) 2.86
Risk factors for financial hardship in patients receiving adjuvant chemotherapy for colon cancer: a population-based exploratory analysis. J Clin Oncol (2012) 2.72
Warfarin pharmacogenetics. Pharmacotherapy (2008) 2.50
Chlorhexidine compared with povidone-iodine solution for vascular catheter-site care: a meta-analysis. Ann Intern Med (2002) 2.43
Why do men choose one treatment over another?: a review of patient decision making for localized prostate cancer. Cancer (2006) 2.42
A formal risk-benefit framework for genomic tests: facilitating the appropriate translation of genomics into clinical practice. Genet Med (2010) 2.40
Economic evaluation of influenza pandemic mitigation strategies in the United States using a stochastic microsimulation transmission model. Value Health (2008) 2.31
Comparison of survival outcomes among cancer patients treated in and out of clinical trials. J Natl Cancer Inst (2014) 2.30
Model transparency and validation: a report of the ISPOR-SMDM Modeling Good Research Practices Task Force-7. Med Decis Making (2012) 2.21
A policy model to evaluate the benefits, risks and costs of warfarin pharmacogenomic testing. Pharmacoeconomics (2010) 2.19
Health care costs among renal cancer patients using pazopanib and sunitinib. J Manag Care Spec Pharm (2015) 2.15
Lung cancer screening with low-dose computed tomography: costs, national expenditures, and cost-effectiveness. J Natl Compr Canc Netw (2012) 2.13
Antimicrobial prophylaxis and outpatient management of fever and neutropenia in adults treated for malignancy: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol (2013) 2.11
Three-year incidence of low back pain in an initially asymptomatic cohort: clinical and imaging risk factors. Spine (Phila Pa 1976) (2005) 2.05
Current status and trends in performance-based risk-sharing arrangements between healthcare payers and medical product manufacturers. Appl Health Econ Health Policy (2014) 2.02
Comparative effectiveness research and policy: experiences conducting a coverage with evidence development study of a therapeutic device. Med Care (2010) 1.92
Stakeholder participation in comparative effectiveness research: defining a framework for effective engagement. J Comp Eff Res (2012) 1.91
Economic return from the Women's Health Initiative estrogen plus progestin clinical trial: a modeling study. Ann Intern Med (2014) 1.87
Breast cancer in limited-resource countries: an overview of the Breast Health Global Initiative 2005 guidelines. Breast J (2006) 1.85
Linking payment to health outcomes: a taxonomy and examination of performance-based reimbursement schemes between healthcare payers and manufacturers. Health Policy (2010) 1.83
Potential impact of task-shifting on costs of antiretroviral therapy and physician supply in Uganda. BMC Health Serv Res (2009) 1.82
Sex, depression, and risk of hospitalization and mortality in chronic obstructive pulmonary disease. Arch Intern Med (2007) 1.77
An analysis of the relative effects of VKORC1 and CYP2C9 variants on anticoagulation related outcomes in warfarin-treated patients. Thromb Haemost (2008) 1.76
Multi-modality mediastinal staging for lung cancer among medicare beneficiaries. J Thorac Oncol (2009) 1.76
Racial disparity in primary and adjuvant treatment for nonmetastatic prostate cancer: SEER-Medicare trends 1991 to 1999. Urology (2004) 1.71
Value-of-information analysis within a stakeholder-driven research prioritization process in a US setting: an application in cancer genomics. Med Decis Making (2013) 1.70
The effect of lung volume reduction surgery on chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med (2007) 1.68
Design, implementation, and first-year outcomes of a value-based drug formulary. J Manag Care Spec Pharm (2015) 1.67
The use, safety and cost of bariatric surgery before and after Medicare's national coverage decision. Ann Surg (2011) 1.63
A model of cost-effectiveness of tissue plasminogen activator in patient subgroups 3 to 4.5 hours after onset of acute ischemic stroke. Ann Emerg Med (2012) 1.58
Cost-effectiveness of peginterferon alpha-2a compared to lamivudine treatment in patients with hepatitis B e antigen positive chronic hepatitis B in Taiwan. J Gastroenterol Hepatol (2007) 1.58
The costs of treating breast cancer in the US: a synthesis of published evidence. Pharmacoeconomics (2009) 1.56
Can't get no satisfaction? Will pay for performance help?: toward an economic framework for understanding performance-based risk-sharing agreements for innovative medical products. Pharmacoeconomics (2010) 1.55
A risk-benefit analysis of factor V Leiden testing to improve pregnancy outcomes: a case study of the capabilities of decision modeling in genomics. Genet Med (2012) 1.52
The ProActive trial protocol - a randomised controlled trial of the efficacy of a family-based, domiciliary intervention programme to increase physical activity among individuals at high risk of diabetes [ISRCTN61323766]. BMC Public Health (2004) 1.51
Cost-effectiveness of diagnostic strategies prior to carotid endarterectomy. Ann Neurol (2005) 1.47
Personalized medicine and genomics: challenges and opportunities in assessing effectiveness, cost-effectiveness, and future research priorities. Med Decis Making (2010) 1.45
Economic outcome of cardiac CT-based evaluation and standard of care for suspected acute coronary syndrome in the emergency department: a decision analytic model. Acad Radiol (2011) 1.45
The timing of elective colectomy in diverticulitis: a decision analysis. J Am Coll Surg (2004) 1.45
Screening for the alpha-adducin Gly460Trp variant in hypertensive patients: a cost-effectiveness analysis. Pharmacogenet Genomics (2006) 1.44
Optimizing CAD diagnosis in China with CT angiography. J Cardiovasc Comput Tomogr (2009) 1.43
Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington state. Surg Obes Relat Dis (2012) 1.42
Building the evidence base for decision making in cancer genomic medicine using comparative effectiveness research. Genet Med (2012) 1.39
INvestigational Vertebroplasty Efficacy and Safety Trial (INVEST): a randomized controlled trial of percutaneous vertebroplasty. BMC Musculoskelet Disord (2007) 1.38
Trends in treatment costs for localized prostate cancer: the healthy screenee effect. Med Care (2007) 1.38
Breast cancer in limited-resource countries: health care systems and public policy. Breast J (2006) 1.35
Stakeholder assessment of the evidence for cancer genomic tests: insights from three case studies. Genet Med (2012) 1.32
Feasibility of incorporating genomic knowledge into electronic medical records for pharmacogenomic clinical decision support. BMC Bioinformatics (2010) 1.32
Costs and survival of patients with colorectal cancer in a health maintenance organization and a preferred provider organization. Med Care (2005) 1.31
Economic burden for informal caregivers of lung and colorectal cancer patients. Oncologist (2010) 1.30
Quantifying losses to the donated blood supply due to donor deferral and miscollection. Transfusion (2004) 1.29
Gene expression profiling and breast cancer care: what are the potential benefits and policy implications? Genet Med (2005) 1.27
Preliminary treatment considerations among men with newly diagnosed prostate cancer. Am J Manag Care (2010) 1.24
Good research practices for measuring drug costs in cost effectiveness analyses: issues and recommendations: the ISPOR Drug Cost Task Force report--Part I. Value Health (2009) 1.22
Utility of repeat head computed tomography after blunt head trauma: a systematic review. J Trauma (2006) 1.20
End-of-life care in the intensive care unit: can we simultaneously increase quality and reduce costs? Am J Respir Crit Care Med (2012) 1.20
Global eradication of measles: an epidemiologic and economic evaluation. J Infect Dis (2011) 1.19
Cost effectiveness of pharmacogenomics: a critical and systematic review. Pharmacoeconomics (2010) 1.19
The efficacy and safety of sibutramine for weight loss: a systematic review. Arch Intern Med (2004) 1.19
Cost effectiveness of a pharmacy-only refill program in a large urban HIV/AIDS clinic in Uganda. PLoS One (2011) 1.19
A cost-effectiveness analysis of intraoperative cholangiography in the prevention of bile duct injury during laparoscopic cholecystectomy. J Am Coll Surg (2003) 1.18
Patterns of use of systemic chemotherapy for Medicare beneficiaries with urothelial bladder cancer. Urol Oncol (2009) 1.17
Prioritization in comparative effectiveness research: the CANCERGEN Experience. Med Care (2012) 1.17
Measuring costs: administrative claims data, clinical trials, and beyond. Med Care (2002) 1.16
Return of incidental findings in genomic medicine: measuring what patients value--development of an instrument to measure preferences for information from next-generation testing (IMPRINT). Genet Med (2013) 1.16
Lifetime implications and cost-effectiveness of using finasteride to prevent prostate cancer. Am J Med (2005) 1.16
The potential clinical and economic outcomes of pharmacogenomic approaches to EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer. Value Health (2008) 1.16
The impact of CFS/ME on employment and productivity in the UK: a cross-sectional study based on the CFS/ME national outcomes database. BMC Health Serv Res (2011) 1.15
Personal bankruptcy after traumatic brain or spinal cord injury: the role of medical debt. Arch Phys Med Rehabil (2009) 1.14
Estimating the costs of induced abortion in Uganda: a model-based analysis. BMC Public Health (2011) 1.13
Physiologic variables and functional status independently predict COPD hospitalizations and emergency department visits in patients with severe COPD. COPD (2007) 1.12
Economic analyses of human genetics services: a systematic review. Genet Med (2005) 1.10
Does adherence make a difference? Results from a community-based aquatic exercise program. Nurs Res (2002) 1.10
Sixteen-slice CT angiography in patients with suspected blunt carotid and vertebral artery injuries. J Am Coll Surg (2006) 1.09